Skip to main content

Table 2 Differences in life expectancy at 65 years comparing medications used to treat seniors with inflammatory bowel disease

From: Real world evidence of the association between medication and life expectancy in elderly inflammatory bowel disease: a population-based cohort study

  Mesalamine Immunomodulator monotherapy Biologic monotherapy Combination therapy Systemic steroids
No therapy
 Females − 3.4 (− 3.9, − 2.9) 3.2 (2.4, 4.1) 2.3 (0.4, 4.2) − 1.8 (− 4.5, 0.9) 7.1 (6.3, 7.8)
 Males − 2.5 (− 3.0, − 2.1) 3.3 (2.5, 4.0) 2.5 (0.7, 4.3) 0.4 (− 2.2, 3.1) 6.8 (6.2, 7.5)
Mesalamine
 Females   6.7 (5.8, 7.5) 5.7 (3.8, 7.6) 1.6 (− 1.1, 4.3) 10.5 (9.7, 11.3)
 Males   5.8 (5.0, 6.6) 5.0 (3.2, 6.8) 3.0 (0.3, 5.6) 9.4 (8.7, 10.0)
Immunomodulator monotherapy
 Females    − 0.9 (− 3.0, 1.1) − 5.1 (− 7.8, − 2.3) 3.8 (2.8, 4.9)
 Males    − 0.8 (− 2.7, 1.1) − 2.8 (− 5.5, − 0.1) 3.6 (2.7, 4.5)
Biologic monotherapy
 Females     − 4.1 (− 7.4, − 0.9) 4.8 (2.8, 6.7)
 Males     − 2.1 (− 5.2, 1.1) 4.3 (2.5, 6.2)
Combination therapy
 Females      8.9 (6.1, 11.6)
 Males      6.4 (3.7, 9.1)
  1. Differences correspond to the medication referenced in the column name subtracted from the medication reference in the row name (i.e., LErow – LEcolumn). Significant differences are indicated in bold font